Abstracts tagged "Disease Activity"

Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Task Toyoda¹, Kerem Abacar¹, Farag Shuweihdi², Megan Sheridan³, Jacqueline Nam³, Ai Lyn Tan⁴, Lesley-Anne Bissell³, Paul Emery⁵ and Kulveer Mankia⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ²Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ⁵University of Leeds, Leeds, England, United Kingdom
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1315 • ACR Convergence 2025
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
Kale Mayor¹, Joey Mercier¹, Yuxi Long², David Robinson¹, Pingzhao Hu², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Western University, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune polyarthritis that typically affects the small joints of the hands and feet. While imaging modalities such as ultrasound…
Abstract Number: 0657 • ACR Convergence 2025
Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
FNU Ruchi¹, Ioana Coman¹, Bryan Blaker¹, Lucero Blaker¹, Joy Park², Jorge Cabezas¹, Dilip Rao¹, +Xiaojing Wang¹, Aparna Godavarthy¹, Marlene Marte Furment³, Sandy Nasr⁴, Sravani Lokineni⁵, Christina Donath⁴, SARA KAHLOWN⁶, Damira Sereda¹, Binod Kc¹, Ilya Ivyanskiy¹, Bhavya Poudyal⁷, Arthur Weinstein⁸, Rosalind Ramsey-Goldman⁹, Michael Weisman¹⁰, Cynthia Aranow¹¹, Mariko Ishimori¹⁰, Kyriakos Kirou¹², Jihad Ben Gabr¹³, Sheetal Rayancha¹⁴, Nancy Olsen¹⁵, Fotios Koumpouras¹⁶, Judith Lin¹⁷, Stephen Faraone¹, Daniel Wallace¹⁸, Michael McDermott¹⁹ and Andras Perl²⁰, ¹SUNY Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, NY, ³Medical Affiliates of Cape Cod, Hyannis, MA, ⁴SUNY Upstate University Hospital, Syracuse, NY, ⁵Deaconess Hospital, Evansville, IN, ⁶Suny upstate medical university, Camillus, NY, ⁷SUNY Upstate Medical University, Cicero, NY, ⁸retired from clinical practice, volunteer academic faculty, Claremont, CA, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Cedars-Sinai Medical Center, LOS ANGELES, CA, ¹¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology & Clinical Immunology, SUNY Upstate Medical University, Syracuse, NY, ¹⁴SUNY Upstate Medical University, Jamesville, NY, ¹⁵Penn State University/Milton S Hershey, Hershey, PA, ¹⁶Yale School of Medicine, New Haven, CT, ¹⁷Ohio State University Wexner Medical Center, Columbus, OH, ¹⁸Cedars Sinai Medical Center, Studio City, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in 5 years. The major causes of death…
Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
Abstract Number: 0425 • ACR Convergence 2025
High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease
Tahnee Spoden¹, Samira Nazzar Romero², Deborah McCurdy³, Alice Hoftman⁴, Sangmee Bae⁵, Jennifer Wang⁴, Ani Shahbazian⁴ and Christina Charles-Schoeman⁶, ¹UCLA, Los Angeles, CA, ²Nemours Children's Health, Orlando, ³UCLA Medical Center, Los Angeles, CA, ⁴UCLA, Los Angeles, ⁵UCLA Rheumatology, Los Angeles, CA, ⁶UCLA Medical Center, Santa Monica, CA
Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
Abstract Number: 0584 • ACR Convergence 2025
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Rodrigo García Salinas¹, Nataly Mejia², Santiago Ruta³ and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital San Martin de La Plata, La Plata, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The concept of difficult-to-Manage axial spondyloarthritis (axSpA D2M), recently introduced by ASAS, describes patients who fail ≥2 lines of b-tsDMARDs treatment and remain active…
Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Joseph F Merola¹, Weihong Yang², Qianyun Li², Helen Doll³, Jason Randall³, Catherine Barbey⁴ and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA, ³Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, ⁴Biogen, Baar, Switzerland
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
Abstract Number: 2253 • ACR Convergence 2025
Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
Misako Higashida-Konishi¹, Keisuke Izumi², Shuntaro Saito Saito³, Hiroki Tabata⁴, Satoshi Hama⁴, Tatsuhiro Oshige⁴, Yutaka Okano⁴, Hisaji Oshima⁴, Katsuya Suzuki⁴, Jiro Sakamoto⁵, Toshikazu Fukami⁵, Kazumichi Minato⁵, Nobuhiko Kajio⁶, Yasushi Kondo³, Hiroaki Taguchi⁶ and Yuko Kaneko³, ¹NHO Tokyo Medical Center, Tokyo Meguroku, Japan, ²Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center/Keio University School of Medicine/TechDoctor, Inc., Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center, Tokyo, Japan, ⁵TechDoctor, Inc., Tokyo, Japan, ⁶Department of Rheumatology, Kawasaki Municipal Hospital, Kanagawa, Japan
Background/Purpose: Previous studies have estimated physical and mental states using wearable device data such as from smartwatches [1–3]. This study aimed to identify digital biomarkers…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 1433 • ACR Convergence 2025
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Yen-An Chang and Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…
Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Elodie Portier¹, Olivier Fogel², Terkia Medkour³, Sophie Hecquet³ and Jérôme AVOUAC³, ¹Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, ²AP-HP, Paris, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Rajaie Namas¹, Sarah Al Qassimi², Rowaida Abdou³, Jawahir Alameri², Reem Alblooshi⁴, Fatima Abdulla⁴, Muriel Ghosn⁴, Amir Malik⁴, Raghda Almaashari⁴, Fulvio Salvo⁴, Mohamed Abuzakouk⁴, Atheer Al Ansari⁵, Hazem Helmy Ali Rifaai⁵, Ahlam Almarzooqi⁶, Asia Mubashir⁷, Ahmed Aldhaheri⁴, Suzan Attar⁸ and Mohamed Elarabi⁹, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³NMC Specialty Hospital Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Cleveland Clinic Abu Dhabi, Abu Dhabi, ⁵Mediclinic, Abu Dhabi, United Arab Emirates, ⁶Emirates Health Services, Sharjah, United Arab Emirates, ⁷Cleveland Clinic, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁹Cleveland Clinic Abu Dhabi, Hannon, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…
Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
MIDHUN SAKRAVARTHY JALANATHAN¹, Mehdi Ali Mirza¹, Vijaya prasanna Parimi², Seethalakshmi S¹ and Tejaswini Ramineni³, ¹ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…
Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Jordan Jones², Michael Holland³, Cara Hoffart², Maria Ibarra³ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].